Estrogen, aging and the cardiovascular system

Future Cardiology

Volumn 5, Issue 1, 2009, Pages 93-103

  Stice, James P ^a   Lee, Jennifer S ^a   Pechenino, Angela S ^a   Knowlton, Anne A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Aging; Endothelial cells; Estrogen; Hormone replacement therapy; Menopause; NF B; Soluble epoxide hydrolase

Indexed keywords

ACETYLCHOLINE; CONJUGATED ESTROGEN; EPOXIDE HYDROLASE; EPOXYICOSATRIENOIC ACID; ESTRADIOL; ESTROGEN; GESTAGEN; GUANYLATE CYCLASE; HEAT SHOCK PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NITRIC OXIDE; PLACEBO;

AGE DISTRIBUTION; AGING; APOPTOSIS; ARTERY INTIMA PROLIFERATION; BLOOD VESSEL TONE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CARDIOVASCULAR SYSTEM; CLINICAL TRIAL; DRUG EFFICACY; ESTROGEN THERAPY; EXTRACELLULAR MATRIX; GENE EXPRESSION; HEART MUSCLE; HEART MUSCLE CELL; HORMONE SUBSTITUTION; HUMAN; HYPOTHESIS; MENOPAUSAL SYNDROME; NONHUMAN; POSTMENOPAUSE; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; RISK ASSESSMENT; VASODILATATION;

AGING; ANIMALS; ANTIOXIDANTS; CARDIOVASCULAR DISEASES; CARDIOVASCULAR SYSTEM; ESTROGENS; FEMALE; HUMANS; POSTMENOPAUSE; RATS;

EID: 67049086583     PISSN: 14796678     EISSN: 17448298     Source Type: Journal    
DOI: 10.2217/14796678.5.1.93     Document Type: Review

References (87)

1. Mendelsohn ME, Karas RH: Molecular and cellular basis of cardiovascular gender differences. Science 308, 1583-1587 (2005).
2. Murphy E, Steenbergen C: Cardioprotection in females: a role for nitric oxide and altered gene expression. Heart Fail. Rev. 12, 293-300 (2007).
3. Choudhry MA, Chaudry IH: 17β-estradiol: a novel hormone for improving immune and cardiovascular responses following trauma-hemorrhage. J. Leukoc. Biol. 83, 518-522 (2008).
4. Mendelsohn ME, Karas RH: The protective effects of estrogen on the cardiovascular system. N. Engl. J. Med. 340, 1801-1811 (1999).
5. Ferrari AU, Radaelli A, Centola M: Invited review: aging and the cardiovascular system. J. Appl. Physiol. 95, 2591-2597 (2003).
6. Taddei S, Virdis A, Mattei P et al.: Aging and endothelial function in normotensive subjects and patients with essential hypertension. Circulation 91, 1981-1987 (1995).
7. Chou TC, Yen MH, Li CY, Ding YA: Alterations of nitric oxide synthase expression with aging and hypertension in rats. Hypertension 31, 643-648 (1998).
8. Lakatta EG: Arterial and cardiac aging major shareholders in cardiovascular disease enterprises: part III: cellular and molecular clues to heart and arterial aging. Circulation 107, 490-497 (2003).
9. Ruetten H, Zabel U, Linz W, Schmidt HH: Downregulation of soluble guanylyl cyclase in young and aging spontaneously hypertensive rats. Circ. Res. 85, 534-541 (1999).
10. Kloss S, Bouloumie A, Mulsch A: Aging and chronic hypertension decrease expression of rat aortic soluble guanylyl cyclase. Hypertension 35, 43-47 (2000).
11. Lin CS, Liu X, Tu R, Chow S, Lue TF: Age-related decrease of protein kinase G activation in vascular smooth muscle cells. Biochem. Biophys. Res. Commun. 287, 244-248 (2001).
12. Arenas IA, Armstrong SJ, Xu Y, Davidge ST: Tumor necrosis factor-α and vascular angiotensin II in estrogen-deficient rats. Hypertension 48, 497-503 (2006).
13. Wassmann S, Baumer AT, Strehlow K et al.: Endothelial dysfunction and oxidative stress during estrogen deficiency in spontaneously hypertensive rats. Circulation 103, 435-441 (2001).
14. Widder J, Pelzer T, von Poser-Klein C et al.: Improvement of endothelial dysfunction by selective estrogen receptor-α stimulation in ovariectomized SHR. Hypertension 42, 991-996 (2003).
15. Stice JP, Eiserich JP, Knowlton AA: Role of aging vs. the loss of estrogens in the reduction in vascular function in female rats. Endocrinology (2008) (Epub ahead of print).
16. Moien-Afshari F, Kenyon E, Choy JC, Battistini B, McManus BM, Laher I: Long-term effects of ovariectomy and estrogen replacement treatment on endothelial function in mature rats. Maturitas 45, 213-223 (2003).
17. Liu MY, Hattori Y, Fukao M, Sato A, Sakuma I, Kanno M: Alterations in EDHF-mediated hyperpolarization and relaxation in mesenteric arteries of female rats in long-term deficiency of oestrogen and during oestrus cycle. Br. J. Pharmacol. 132, 1035-1046 (2001).
18. Sakuma I, Liu MY, Sato A et al.: Endothelium-dependent hyperpolarization and relaxation in mesenteric arteries of middle-aged rats: influence of oestrogen. Br. J. Pharmacol. 135, 48-54 (2002).
19. Lakatta EG: Age-associated cardiovascular changes in health: impact on cardiovascular disease in older persons. Heart Fail. Rev. 7, 29-49 (2002).
20. Alvarez A, Hermenegildo C, Issekutz AC, Esplugues JV, Sanz MJ: Estrogens inhibit angiotensin II induced leukocyte-endothelial cell interactions in vivo via rapid endothelial nitric oxide synthase and cyclooxygenase activation. Circ. Res. 91, 1142-1150 (2002).
21. 2+ mobilization. Circ. Res. 81, 885-892 (1997).
22. Cid MC, Schnaper HW, Kleinman HK: Estrogens and the vascular endothelium. Ann. NY Acad. Sci. 966, 143-157 (2002).
23. Dubey RK, Jackson EK, Gillespie DG, Zacharia LC, Imthurn B, Keller PJ: Clinically used estrogens differentially inhibit human aortic smooth muscle cell growth and mitogen-activated protein kinase activity. Arterioscler. Thromb. Vasc. Biol. 20, 964-972 (2000).
24. Zhang Y, Davidge ST: Estrogen replacement increases coronary artery distensibility in ovariectomized rats. Can. J. Physiol. Pharmacol. 77, 75-78 (1999).
25. Qiu H, Depre C, Ghosh K et al.: Mechanism of gender-specific differences in aortic stiffness with aging in nonhuman primates. Circulation 116, 669-676 (2007).
26. Wu JM, Zelinski MB, Ingram DK, Ottinger MA: Ovarian aging and menopause: current theories, hypotheses, and research models. Exp. Biol. Med. (Maywood) 230, 818-828 (2005).
27. Xu Y, Arenas IA, Armstrong SJ, Davidge ST: Estrogen modulation of left ventricular remodeling in the aged heart. Cardiovasc. Res. 57, 388-394 (2003).
28. Dean SA, Tan J, O'Brien ER, Leenen FH: 17β-estradiol downregulates tissue angiotensin-converting enzyme and ANG II type 1 receptor in female rats. Am. J. Physiol. Regul. Integr. Comp. Physiol. 288, R759-R766 (2005).
29. Pedram, A, Razandi M, Lubahn D, Liu J, Vannan M, Levin ER: Estrogen inhibits cardiac hypertrophy: role of estrogen receptor-β to inhibit calcineurin. Endocrinology 149, 3361-3369 (2008).
30. Pedram A, Razandi M, Aitkenhead M, Levin ER: Estrogen inhibits cardiomyocyte hypertrophy in vitro. Antagonism of calcineurin-related hypertrophy through induction of MCIP1. J. Biol. Chem. 280, 26339-26348 (2005).
31. Olivetti G, Giordano G, Corradi D et al.: Gender differences and aging: effects on the human heart. J. Am. Coll. Cardiol. 26, 1068-1079 (1995).
32. Patten RD, Pourati I, Aronovitz MJ et al.: 17β-estradiol reduces cardiomyocyte apoptosis in vivo and in vitro via activation of phospho-inositide-3 kinase/Akt signaling. Circ. Res. 95, 692-699 (2004).
33. Kim JK, Pedram A, Razandi M, Levin ER: Estrogen prevents cardiomyocyte apoptosis through inhibition of reactive oxygen species and differential regulation of p38 kinase isoforms. J. Biol. Chem. 281, 6760-6767 (2006).
34. Hamilton KL, Lin L, Wang Y, Knowlton AA: Effect of ovariectomy on cardiac gene expression: inflammation and changes in SOCS gene expression. Physiol. Genomics 32, 254-263 (2008).
35. Jazbutyte V, Hu K, Kruchten P et al.: Aging reduces the efficacy of estrogen substitution to attenuate cardiac hypertrophy in female spontaneously hypertensive rats. Hypertension 48, 579-586 (2006).
36. Sharkey LC, Holycross BJ, Park S et al.: Effect of ovariectomy and estrogen replacement on cardiovascular disease in heart failure-prone SHHF/Mcc- fa cp rats. J. Mol. Cell Cardiol. 31, 1527-1537 (1999).
37. Roth DA, White CD, Podolin DA, Mazzeo RS: Alterations in myocardial signal transduction due to aging and chronic dynamic exercise. J. Appl. Physiol. 84, 177-184 (1998).
38. Muscari C, Giaccari A, Giordano E, Clo C, Guarnieri C, Caldarera CM: Role of reactive oxygen species in cardiovascular aging. Mol. Cell Biochem. 160-161, 159-166 (1996).
39. Chung HY, Sung B, Jung KJ, Zou Y, Yu BP: The molecular inflammatory process in aging. Antioxid. Redox Signal. 8, 572-581 (2006).
40. Knowlton AA: The role of heat shock proteins in the heart. J. Mol. Cell Cardiol. 27, 121-131 (1995).
41. Voss MR, Stallone JN, Li M, Cornelussen RN, Knuefermann P, Knowlton AA: Gender differences in the expression of heat shock proteins: the effect of estrogen. Am. J. Physiol. Heart Circ. Physiol. 285, 687-692 (2003).
42. Hamilton KL, Gupta S, Knowlton AA: Estrogen and regulation of heat shock protein expression in female cardiomyocytes: cross-talk with NFκB signaling. J. Mol. Cell Cardiol. 36, 577-584 (2004).
43. Hamilton KL, Mbai FN, Gupta S, Knowlton AA: Estrogen, heat shock proteins, and NFκB in human vascular endothelium. Arterioscler. Thromb. Vasc. Biol. 24, 1628-1633 (2004).
44. Stice JP, Knowlton AA: Estrogen, NFκB, and the heat shock response. Mol. Med. 14, 517-527 (2008).
45. Bongrazio M, Comini L, Gaia G, Bachetti T, Ferrari R: Hypertension, aging, and myocardial synthesis of heat-shock protein 72. Hypertension 24, 620-624 (1994).
46. Demirel HA, Hamilton KL, Shanely RA, Tumer N, Koroly MJ, Powers SK: Age and attenuation of exercise-induced myocardial HSP72 accumulation. Am. J. Physiol. Heart Circ. Physiol. 285, H1609-H1615 (2003).
47. Leger JP, Smith FM, Currie RW: Confocal microscopic localization of constitutive and heat shock-induced proteins HSP70 and HSP27 in the rat heart. Circulation 102, 1703-1709 (2000).
48. Chiamvimonvat N, Ho CM, Tsai HJ, Hammock BD: The soluble epoxide hydrolase as a pharmaceutical target for hypertension. J. Cardiovasc. Pharmacol. 50, 225-237 (2007).
49. Yu Z, Xu F, Huse LM et al.: Soluble epoxide hydrolase regulates hydrolysis of vasoactive epoxyeicosatrienoic acids. Circ. Res. 87, 992-998 (2000).
50. Inceoglu B, Schmelzer KR, Morisseau C, Jinks SL, Hammock BD: Soluble epoxide hydrolase inhibition reveals novel biological functions of epoxyeicosatrienoic acids (EETs). Prostaglandins Other Lipid Mediat. 82, 42-49 (2007).
51. Imig JD, Zhao X, Capdevila JH, Morisseau C, Hammock BD: Soluble epoxide hydrolase inhibition lowers arterial blood pressure in angiotensin II hypertension. Hypertension 39, 690-694 (2002).
52. Fornage M, Lee CR, Doris PA et al.: The soluble epoxide hydrolase gene harbors sequence variation associated with susceptibility to and protection from incident ischemic stroke. Hum. Mol. Genet. 14, 2829-2837 (2005).
53. Node K, Huo Y, Ruan X et al.: Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. Science 285, 1276-1279 (1999).
54. Kozak W, Kluger MJ, Kozak A, Wachulec M, Dokladny K: Role of cytochrome P-450 in endogenous antipyresis. Am. J. Physiol. Regul. Integr. Comp. Physiol. 279, R455-R460 (2000).
55. Seubert JM, Sinal CJ, Graves J et al.: Role of soluble epoxide hydrolase in postischemic recovery ofheart contractile function. Circ. Res. 99, 442-450 (2006).
56. Xu D, Li N, He Y et al.: Prevention and reversal of cardiac hypertrophy by soluble epoxide hydrolase inhibitors. Proc. Natl Acad. Sci. USA 103, 18733-18738 (2006).
57. Zhang W, Koerner IP, Noppens R et al.: Soluble epoxide hydrolase: a novel therapeutic target in stroke. J. Cereb. Blood Flow Metab. 27, 1931-1940 (2007).
58. Gschwendtner A, Ripke S, Freilinger T et al.: Genetic variation in soluble epoxide hydrolase (EPHX2) is associated with an increased risk of ischemic stroke in white Europeans. Stroke 39, 1593-15966 (2008).
59. Lee CR, North KE, Bray MS et al.: Genetic variation in soluble epoxide hydrolase (EPHX2) and risk of coronary heart disease: The Atherosclerosis Risk in Communities (ARIC) study. Hum. Mol. Genet. 15, 1640-1649 (2006).
60. Wei Q, Doris PA, Pollizotto, MV et al.: Sequence variation in the soluble epoxide hydrolase gene and subclinical coronary atherosclerosis: interaction with cigarette smoking. Atherosclerosis 190, 26-34 (2007).
61. Fornage M, Boerwinkle E, Doris PA, Jacobs D, Liu K, Wong ND: Polymorphism of the soluble epoxide hydrolase is associated with coronary artery calcification in African-American subjects: The Coronary Artery Risk Development in Young Adults (CARDIA) study. Circulation 109, 335-339 (2004).
62. Fornage M, Hinojos CA, Nurowska BW et al.: Polymorphism in soluble epoxide, hydrolase and blood pressure in spontaneously hypertensive rats. Hypertension 40, 485-490 (2002).
63. Koerner IP, Zhang W, Cheng J, Parker S, Hurn PD, Alkayed NJ: Soluble epoxide hydrolase: regulation by estrogen and role in the inflammatory response to cerebral ischemia. Front. Biosci. 13, 2833-2841 (2008).
64. Zhang W, Hurn PD, Alkayed NJ. Selective targeting of soluble epoxide hydrolase for neuroprotection in hormone-depleted female brain. Program and abstracts of the Society of Neuroscience Meeting. San Diego, CA, USA 3-7 Novembee, 2007 (Abstract 376 9).
65. Fleming I: Cytochrome p450 and vascular homeostasis. Circ. Res. 89, 753-762 (2001).
66. Athirakul K, Bradbury Dagger JA, Graves JP et al.: Increased blood pressure in mice lacking cytochrome P450 2J5. FASEB J. (2008) (Epub ahead of print).
67. Barrett-Connor E, Bush TL: Estrogen and coronary heart disease in women. JAMA 265, 1861-1967 (1991).
68. Grady D, Rubin SM, Petitti DB et al.: Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann. Intern. Med. 117, 1016-1037 (1992).
69. Barrett-Connor E, Grady D: Hormone replacement therapy, heart disease, and other considerations. Annu. Rev. Public Health 19, 55-72 (1998).
70. Hulley S, Grady D, Bush T et al.: Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 280, 605-613 (1998).
71. Grady D, Herrington D, Bittner V et al.: Cardiovascular disease outcomes during 6.8 years of hormoxe therapy: Heart and Estrogen/ progestin Replacement Study follow-up (HERS II). JAMA 288, 49-57 (2002).
72. Rossouw JE, Anderson GL, Prentice RL et al.: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288, 321-333 (2002).
73. Anderson GL, Limacher M, Assaf AR et al.: Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 1701-1712 (2004).
74. Hodis HN: Assessing benefits and risks of hormone therapy in (2008): new evidence, especially with regard to the heart. Cleve. Clin. J. Med. 75 (Suppl. 4), S3-SI2 (2008).
75. Turgeon JL, Carr MC, Maki PM, Mendelsohn ME, Wise PM: Complex actions of sex steroids in adipose tissue, the cardiovascular system, and brain: insights from basic science and clinical studies. Endocr. Rev. 27, 575-605 (2006). Also available at: http://edrv.endojournals.org/cgi/ reprint/27/6/575
76. Sowers MR, Randolph J Jr, Jannausch M, Lasley B, Jackson E, McConnell D: Levels of sex steroid and cardiovascular disease measures in premenopausal and hormone-treated women at midlife: implications for the 'timing hypothesis'. Arch. Intern. Med. 168, 2146-2153 (2008).
77. Atsma F, van der Schouw YT, Grobbee DE, Hoes AW, Bartelink ML: No added value of age at menopause and the lifetime cumulative number of menstrual cycles for cardiovascular risk prediction in postmenopausal women. Int J Cardiol. 130, 190-195 (2008).
78. Rossouw JE, Prentice RL, Manson JE et al.: Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 297, 1465-1477 (2007).
79. Manson JE, Allison MA, Rossouw JE et al.: Estrogen therapy and coronary-artery calcification. N. Engl. J. Med. 356, 2591-2602 (2007).
80. Manson JE, Bassuk SS: Invited commentary: hormone therapy and risk of coronary heart disease why renew the focus on the early years of menopause? Am. J. Epidemiol. 166, 511-517 (2007).
81. Barrett-Connor E: Hormones and heart disease in women: the timing hypothesis. Am. J. Epidemiol. 166, 506-510 (2007).
82. Wise PM: Estrogens and cerebrovascular stroke: what do animal models teach us? Ann. NY Acad. Sci. 1052, 225-232 (2005).
83. Wise PM: Estrogen therapy: does it help or burt the adult and aging brain? Insights derived from animal models. Neuroscience 138, 831-835 (2006).
84. Turgeon JL, McDonnell DP, Martin KA, Wise PM: Hormone therapy: physiological complexity belies therapeutic simplicity. Science 304, 1269-1273 (2004).
85. Harman SM, Brinton EA, Cedars M et al.: KEEPS: The Kronos Early Estrogen Prevention Study. Climacteric 8, 3-12 (2005).
86. Estrogen and progestogen use in peri- and postmenopausal women: March (2007) position statement of the North American Menopause Society. Menopause 14, 168-182 (2007).
87. van der Schouw YT, Grobbee DE: Menopausal complaints, oestrogens, and heart disease risk: an explanation for discrepant findings on the benefits of post-menopausal hormone therapy. Eur. Heart J. 26, 1358-1361 (2005).